trending Market Intelligence /marketintelligence/en/news-insights/trending/c7r_cvot85jyxwalnrlyzw2 content esgSubNav
In This List

ZIOPHARM Oncology adds CEO to board; chief medical officer steps down

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery


ZIOPHARM Oncology adds CEO to board; chief medical officer steps down

ZIOPHARM Oncology Inc., an immuno-oncology biotechnology company, appointed its CEO, Laurence Cooper, as director, effective Oct. 16.

In addition, the company said in its press release that Francois Lebel is stepping down as the chief medical officer and executive vice president of research and development, effective Oct. 26.

Boston-based ZIOPHARM focuses on acquiring, developing and marketing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens.

Cooper said in the company's press release that ZIOPHARM is developing and expanding research and development as well as clinical development teams to support the cancer therapy Controlled IL-12 and Sleeping Beauty CAR-T and TCR-T programs.